← Back to headlines
Neurocrine to Acquire Soleno Therapeutics for $2.9 Billion to Boost Rare Disease Treatment
Neurocrine Biosciences has announced an all-cash buyout of Soleno Therapeutics for $2.9 billion, valuing shares at $53 each, specifically to acquire a treatment for a rare disease that causes relentless hunger.
6 Apr, 13:53 — 6 Apr, 14:47
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (32/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left
Center1
Center (1)
Reuters
Right1
Right (1)
wsj
Far R
Geographic diversity— 2 regions9/34
US1Intl1
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
ReutersVery High2d ago
Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout - Reuters
Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout Reuters
Read full article →wsjHigh1d ago
Neurocrine to Buy Soleno for Treatment for Rare Disease That Causes Relentless Hunger - WSJ
Neurocrine to Buy Soleno for Treatment for Rare Disease That Causes Relentless Hunger WSJ
Read full article →Coverage Timeline
First report: Reuters · 6 Apr, 13:53|Full coverage: 2 · 53m|Window: 53m
Left-leaningCenterRight-leaning
